Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
about
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of agePneumococcal vaccines for sickle cell diseaseSafety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure dataPriming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.Should the new pneumococcal vaccine be used in high-risk children?Current state of pneumococcal vaccines.Conjugated heptavalent pneumococcal vaccine.Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009.Immunogenicity of pneumococcal vaccination in a patient with sickle hemoglobinopathy: a case report.The safety of 7-valent pneumococcal conjugate vaccine.Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.Adherence to prophylactic antibiotic guidelines among Medicaid infants with sickle cell disease.Assessing the Immunogenic Response of a Single Center's Pneumococcal Vaccination Protocol in Sickle Cell Disease.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.How to manage vaccinations in children with cancer.PCVs in individuals at increased risk of pneumococcal disease: a literature review.Safety and tolerability of pneumococcal vaccines in children.13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.Protein conjugate pneumococcal vaccines.Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions.Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
P2860
Q24245934-FCD84FCB-0C4E-4C59-80AC-DDE5463B1DFCQ24247418-5F1F4B7F-4437-4350-B391-061B36175595Q31158788-8AA47EFF-E91E-4994-B88E-277266DED7C3Q34072420-2EEAAF30-BEE8-494E-90A6-27BA10AE26DDQ34569275-36503494-947C-457D-8FF1-8C16E7B91215Q34590621-365EC058-173E-4022-92DF-781F46EF662CQ34712891-60D94083-8942-4C0E-AD25-F0FB199BBD65Q34744239-9553E464-DE15-429A-80AB-F51271EFBE8CQ34796973-13C97E08-8741-48FE-B31A-06718CFF3780Q35902336-6C1BE85A-43F1-4948-B67A-9135DC685325Q35924895-A089A829-52B4-4D92-ABD1-7DEC2DA850D5Q36190995-47EB38F1-5E6D-4005-A924-BB8AB88238E3Q36452316-7A73D54F-347B-4A5A-91BC-A9988026D716Q36680138-7B299571-24E3-4731-8C71-B7196D585AE9Q36711643-B3A80DF2-E3EE-41BD-9874-6770CBCF5729Q37613613-9F7FAA6B-3ED6-4833-A38F-C971B801728EQ37621061-881F94AE-97D6-45D9-82B7-BA97DE8C4DB3Q37939743-9601276E-18AD-445C-88DA-258E1FFCFA57Q38530267-DCEA03F5-A17F-435F-BF40-DDF1B5003316Q38753554-E820C95C-E0AA-45AD-9402-F19A09D63993Q41382795-6FC8245F-C211-4C9D-876A-A5FD4898F7B8Q42776843-CC7BC8B3-B323-44A7-8EDB-B71CC7CCFE80Q44302778-74808D3E-689E-457F-A7F5-B7ACF1F0A59CQ53236896-4767E3C2-F542-408E-8E95-EB6CB73D0732
P2860
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM
@nl
Safety and immunogenicity of h ...... Conjugate Vaccine Study Group.
@en
type
label
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM
@nl
Safety and immunogenicity of h ...... Conjugate Vaccine Study Group.
@en
prefLabel
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM
@nl
Safety and immunogenicity of h ...... Conjugate Vaccine Study Group.
@en
P2093
P356
P1433
P1476
Safety and immunogenicity of h ...... Conjugate Vaccine Study Group.
@en
P2093
Eskenazi A
Gootenberg JE
Lederman HM
O'Brien KL
Santosham M
P304
P356
10.1542/PEDS.106.5.965
P407
P577
2000-11-01T00:00:00Z